Placebo-controlled, double-blind randomized naturalistic microdosing study (n=34) testing two 0.5 g dried Psilocybe cubensis sessions versus matched placebo in healthy microdosing volunteers with EEG, cognitive, behavioural and self-report outcomes.
This naturalistic, double-blind, placebo-controlled study examines acute and short-term effects of low doses of psilocybin (0.5 g dried Psilocybe cubensis, ~0.8 mg psilocybin) taken in participants' usual environments.
Two dosing sessions (active vs placebo) are administered in randomized order one week apart; outcomes include resting-state EEG, evoked potentials, cognitive task performance, creativity measures, actigraphy-derived sleep and behavioural metrics, natural language analysis, and standardised self-report instruments.
Participants are intrinsically motivated microdosers and will follow the study protocol while wearing a smartwatch for continuous activity and sleep monitoring during each measurement week.
0.5 g dried Psilocybe cubensis in gel capsules; two dosing sessions separated by one week; randomized order, double-blind.
~0.8 mg psilocybin per 0.5 g dried mushroom material; administered in gel capsules in natural settings
Matched 0.5 g dried edible non-psychoactive mushroom material in gel capsules; two sessions, randomized order.
Inactive dried edible mushroom material in gel capsules